Browse our anti-TRAF6 (TRAF6) Antibodies

Human TNF Receptor-Associated Factor 6 (TRAF6) interaction partners

1. Results show that TRAF6 is upregulated in SACC samples, especially in SACC with metastasis, which is closely correlated with an aggressive phenotype and shorter life survival span in SACC patients.

2. Genetic polymorphisms of TRAF6 are associated with decreased peritoneal immune activation and an increased risk of spontaneous bacterial peritonitis.

3. The overexpression of miR-146a significantly increased the ErbB4 expression, decreased the expression of TRAF6, IRAK1, caspase 3, and the phosphorylation level of NF-kappaB, and also increased the Bcl-2/Bax ratio, suggesting the inhibition of inflammation and apoptosis.

4. TRAF6 can promote the proliferation of stromal cells of benign prostatic hyperplasia via Akt/mTOR signaling.

5. Study identified IRAK1 and TRAF6 are direct targets of miR-146a in cervical cancer cells. Their expression is downregulated by miR-146a to promote cell viability.

6. Immune profiling of human prostate epithelial cells in health and pathology determined by expression of p38/TRAF-6/ERK MAP kinases pathways has been reported.

7. Downregulation of miR-124 in human osteosarcoma tissues and cell lines may increase the expression of TRAF6 protein. miR-124 may inhibit cell cycle progression and invasion of osteosarcoma cells, and promote apoptosis by regulating TRAF6.

8. Low TRAF6 expression is associated with posterior longitudinal ligament ossification.

9. these results suggest that miR-146a-5p affects proliferation and apoptosis in a cellular context-dependent manner and selectively disarms the TRAF6-mediated branch of the TGF-beta signaling in oral squamous cell carcinoma cell lines by sparing Smad4 involvement

10. MALT1 and TRAF6 cooperatively interact with CARMA1-BCL10 filaments and form CARMA1-BCL10-MALT1-TRAF6 signalosome.

11. our data demonstrated that miR146b5p, as a tumor suppressor, mediated temozolomide resistance in GBM cells through negatively regulating TRAF6 expression, indicating that miR146b5p and its targeted genes would be potential therapeutic targets for glioma therapy.

12. genetic association studies in Han population in southern China: Data suggest that, in subjects with type 2 diabetes, an SNP in NLRX1 (rs4245191) is associated with macro-vascular complications and cerebral infarction in the population studied; no such association was found for two other SNPs in NLRX1 (rs10790286, rs561830) or for two SNPs in TRAF6 (rs5030445, rs16928973). (NLRX1 = NLR family member-X1)

13. protein-protein interaction studies on TRAF6 and BSG to get molecular level insights of the reactions.

14. miR-146a suppresses the inflammatory response in human white adipocytes via targeting the expression of IRAK1 and TRAF6.

15. miRNA146a expression was significantly higher in hepatitis C patients with a best cut off value 1.63 to discriminate between hepatitis C patients and healthy controls. Meanwhile, it was negatively correlated to IRAK1 and TRAF6 levels and positively correlated to viral load in hepatitis C patients.

16. Suggest role for EBV-EBER1 in the induction of increased TRAF6 expression in the peripheral B cells of Sjogren's patients.

17. theses results indicate that miR-146b-5p inhibits tumor growth and metastasis of hepatocellular carcinoma by targeting TRAF6 mediated Akt phosphorylation

18. TRAF6 plays direct roles in the pro-inflammatory effects and proliferation of Rheumatoid arthritis (RA) fibroblast-like synoviocytes. TRAF6 may serve as a potential treatment target in RA.

19. MiR-146a declined, while TRAF6 increased in lupus nephritis patients compared with healthy controls.

20. Epigallocatechin-3-gallate is a novel E3 ubiquitin ligase inhibitor that could be used to target TRAF6 activity in melanoma cells, inhibiting cell proliferation/migration.

Mouse (Murine) TNF Receptor-Associated Factor 6 (TRAF6) interaction partners

1. The data suggest that TFAF6 inhibition reduces choroidal neovascularization formation via down-regulating expression of HIF-1a and VEGF and activation of macrophages and microglia.

2. Traf6 plays a crucial role in regulating M1 osteoclast and M2 foreign body giant cell polarization.

3. Authors report that the deletion of TRAF6 in hematopoietic lineage cells resulted in the upregulation of HSPCs in the fetal liver at the prenatal period. However, in the early postnatal period, deletion of TRAF6 drastically diminished HSPCs in the bone marrow (BM), with severe defects in BM development and extramedullary hematopoiesis in the spleen being identified.

4. Study demonstrated that TRAF6 plays an important role in the process of aseptic inflammatory loosening caused by periprosthetic debris, and Low intensity pulsed ultrasound was found to inhibit such inflammation through increasing the level of FBXL2, and further increasing ubiquitination of TRAF6.

5. atorvastatin treatment may protect BV2 microglia and hippocampal neurons from oxygenglucose deprivationinduced neuronal inflammatory injury by suppressing the TLR4/TRAF6/NFkappaB pathway. This may provide a potential strategy for the treatment of neuronal injury.

6. these findings identify IPMK as a key determinant of TRAF6 stability and elucidate the physiological function of IPMK in TLR-induced innate immunity.

7. Results demonstrate that TRAF6 interacts with MyD88 and suggest that TRAF6 participates in protection from basal autophagy.

8. Klf4 Alleviates Lipopolysaccharide-Induced Inflammation by Inducing Expression of MCP-1 Induced Protein 1 to Deubiquitinate TRAF6.

9. TRAF6 RING dimer employs a concerted allosteric mechanism using both subunits of the TRAF6 dimer to promote ubiquitin (Ub) transfer.

10. Low TRAF6 expression is associated with posterior longitudinal ligament ossification.

11. miR-146a-mediated control of Traf6 expression Is required for the attenuation of proinflammatory cytokine responses, control of T cell tolerance, and prevention of autoimmunity.

12. Data indicate TNF receptor associated factor 6 (TRAF6) as an essential molecular switch leading to cardiac hypertrophy in a transforming growth factor beta-activated kinase 1 (TAK1), -dependent manner.

13. Berberine hydrochloride targets TRAF6 and NFATc1.

14. protein-protein interaction studies on TRAF6 and BSG to get molecular level insights of the reactions.

15. The authors found that keratin 8 suppressed toll-like receptor-induced nuclear factor (NF)-kappaB activation and interacted with the adaptor tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) to prevent its polyubiquitination.

16. MiR-146a/ MiR-146b could down-regulate the TRAF6 and IRAK1 expression and promote proliferation, migration and angiogenesis ability of endothelial progenitor cells, which could be important for recovery of patients with hyperacute ischemic stroke.

17. TRAF6 coiled-coil oligomerization domain primes its interaction with Ubc13/Ub~Ubc13 to confer processivity. Long polyUb chain assembly requires coiled-coil domain of TRAF6

18. TRAF6 is a key promoter of ischemic signaling cascades and neuronal death after cerebral ischemia/reperfusion injury. TRAF6 upregulation binds and ubiquitinates Rac1 directly, which promotes neuron death through neuroinflammation and neuro-oxidative signals.

19. Data provide a novel association between WDFY3 and the RANKL-induced osteoclastogenesis pathway via the modulation of TRAF6.

20. this study shows that TRAF6 is necessary for the nontranscriptional priming of NLRP3 inflammasome by TLR/IL-1R derived signals

Fruit Fly (Drosophila melanogaster) TNF Receptor-Associated Factor 6 (TRAF6) interaction partners

1. we found that reactive oxygen species-induced autophagy acts as a negative feedback regulator of JNK activity by dissociating Atg9/mAtg9 from dTRAF2/TRAF6 in Drosophila.

2. null mutant of DTRAF2 showed immune deficiencies in which NF-kappaB nuclear translocation and antimicrobial gene transcription against microbial infection were severely impaired

Zebrafish TNF Receptor-Associated Factor 6 (TRAF6) interaction partners

1. we have now analyzed the in vivo function of Traf6 in the innate immune response without interference of adaptive immunity

2. Full-length traf6 was functionally characterized.